🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

Important awareness piece by BBC News (UK) reminding us that lung cancer is on the rise in people who have never smoked. These are different types of lung cancer and we’re still learning why they occur: radon, pollution, unknown. All of us are at risk. bbc.com/future/article…

🚨 TODAY Don't miss today's roundtable on the latest progress in treating small cell lung cancer with renowned experts, Solange Peters, Giannis Mountzios and Jacob sands! #ASCO25 #LCSM ⏰ 17ᵗʰ June at 5PM CEST Tune in for free ⬇️

Global trends in lung cancer reported Lung Cancer Journal. Notable for general increase in lung cancer incidence and mortality in women, esp France (incidence) and Norway (mortality). Increases noted in some countries despite decrease in tobacco use (Japan). lungcancerjournal.info/article/S0169-…

📣Updated ESMO #ClinicalPracticeGuideline recommendations in the non-oncogene-addicted metastatic #NSCLC: new 1L Tx options approved. 🔗 ow.ly/kzQF50Wa0lf #LungCancer #mNSCLC #ESMOGuidelines

Pragmatic Randomized Study of Afatinib Versus Chemotherapy for Patients With Non–Small Cell Lung Cancer With Uncommon Epidermal Growth Factor Receptor Mutations: ACHILLES/TORG1834 | Journal of Clinical Oncology ascopubs.org/doi/abs/10.120…

Dr. Tony Mok discusses #EGFR at #CIOT25. Emerging combinations like MARIPOSA and FLAURA2 improving outcomes - key is patient selection. Chemo-IO is out based on CM722 and KN789 but HARMONi could change things if OS superior. ADCs in 3L instead of 2L?

Approach to #EGFR TKI resistance from Tony Mok at #CIOT25. Complexity continues to grow.

Dr. Nicolas Girard discusses #EGFR exon 20 insertions at #CIOT25 - amivantamab plus chemo (PAPILLON) is our standard but outcomes vary by specific mutation. New agents to watch include furmonertinib, sunvozertinib, zipalertinib, and more in the pipeline!

Dr. Ben Solomon shows the massive progress we have seen in #ALK therapy for NSCLC at #CIOT25. Profound PFS benefit with lorlatinib in CROWN. Will NVL-655 / neladalkib eclipse those marks?

Dr. Alexander Drilon MD at #CIOT25 clearly favoring taletrectinib as 1L for #ROS1 NSCLC - potential and better tox profile. NVL-520 zidesamtinib poised to potentially be best in class. For #RET, after selpercatinib or pralsetinib, few options. EP0031 is one in development.

Dr. Suresh S. Ramalingam, MD, FASCO at #CIOT25 outlines the role that targeted therapy plays in early stage #EGFR NSCLC. ADAURA shows the benefit of osimertinib after surgery. NEOADAURA shows modest MPR but unlikely to impact OS. LAURA shows benefit after chemoradiation- but is it a cure?

At #CIOT25, Dr. Ben Solomon explains that for resected #ALK NSCLC, adjuvant alectinib is our standard with consistent benefit across stages. TP53 comutation powerful negative prognostic factor. Ongoing studies to define neoadjuvant activity and role post chemoradiation.

#ELIXR25🍁 Getting ready for the ‘Frenemies’ debate! Neoadj vs Periop ChemoIO in resectable NSCLC 🥊Tina Cascone🇺🇸 MD Anderson Cancer Center Versus 🥊Patrick Forde🇮🇪Trinity St James's Cancer Institute Let the games begin! OncoAlert #LCSM

ESMO has updated guidelines for non oncogene addicted metastatic NSCLC #LCSM doi.org/10.1016/j.anno…

⚠️ Osimertinib & the Heart: Meta-Analysis Update 🫀 Cardiotoxicity in EGFR-mut NSCLC: 4.0% overall 📈 Most common AEs: – QT prolongation: 6.03% – Atrial fibrillation: 1.5% – Heart failure: 1.21% 🧪 Higher risk in RCTs (4.98%) & combos (4.89%) 🌍 Most prevalent in North America

Review on next generation immunotherapies in NSCLC doi.org/10.1038/s41571… #LCSM d.planchard Aɴᴛᴏɴɪᴏ Pᴀssᴀʀᴏ Benjamin Besse Sanjay Popat Giannis Mountzios Fred R. Hirsch Suresh S. Ramalingam, MD, FASCO Christine Lovly, MD, PhD, FASCO Hossein Borghaei, DO Joshua Reuss Chul Kim Biagio Ricciuti, MD, PhD Aakash Desai, MD, MPH, FASCO Eric K. Singhi, MD

#SCLC at its best‼️An exquisite Nature Cancer review on recent progress by Anish J Thomas MD, FACC, FSCAI et al + legendary Dr Giaconne focusing: ⭐️ASCL1/DLL3/NOTCH interplay to regulate neuroendocrine transcription dynamics ⭐️ BiTEs/TriTEs/ BiTE ADCs/CARs trial landscape Don’t miss it!!

Big news from JTO & JTO CRR! 📘 JTO Impact Factor: 20.8 🔹 #3 in Respiratory Medicine 🔹 #13 in Oncology A high-impact leader in thoracic oncology! 👏 for JTO CRR with an IF of 3.5, rising in both oncology & respiratory rankings! ➡️ bit.ly/3ZGbIol

How to interpret p-values 😅

Qx raise about role of ADCs in NSCLC. Data in NSCLC and AGA🧬most in mEGFR at osimertinib. but should be applied as monotherapy? With osimertinib? Some data in NSCLC with other AGA but no intracranial data. There is a room for improvement. We need to define the population